No Data
Ceribell to Report First Quarter 2025 Financial Results on May 8, 2025
TD Cowen Maintains Ceribell(CBLL.US) With Buy Rating, Maintains Target Price $36
Ceribell, Inc.: Promising Growth Trajectory and Strong Market Potential Reinforce Buy Rating
CeriBell Says FDA Clears Electrographic Seizure Detection Algorithm
Express News | FDA Clears Ceribell’s Clarity™ Algorithm for Pediatric Patients, Making Ceribell the First and Only FDA-Cleared AI Technology for Detection of Electrographic Seizures in Patients Ages 1 Year and Older
BofA Securities Maintains Ceribell(CBLL.US) With Buy Rating, Maintains Target Price $32